Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for INGREZZA ® (valbenazine) oral granules, a new sprinkle formulation of INGREZZA.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for INGREZZA ® (valbenazine) oral granules, a new sprinkle formulation of INGREZZA.